XML 26 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Deficit - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
 [1]
Retained Earnings
Treasury Stock
Noncontrolling Interests in Subsidiaries
Cumulative effect of adoption of ASU 2016-13
 [2]
Cumulative effect of adoption of ASU 2016-13
Retained Earnings
 [2]
Adjusted balance
Adjusted balance
Common Stock
Adjusted balance
Additional Paid-In Capital
Adjusted balance
Accumulated Other Comprehensive Loss
 [1]
Adjusted balance
Retained Earnings
Adjusted balance
Treasury Stock
Adjusted balance
Noncontrolling Interests in Subsidiaries
Beginning balance (in shares) at Dec. 29, 2019   31,894                 31,894          
Beginning balance at Dec. 29, 2019 $ (316,656) $ 447 $ 219,047 $ (10,185) $ 205,697 $ (747,327) $ 15,665 $ (1,066) $ (1,066) $ (317,722) $ 447 $ 219,047 $ (10,185) $ 204,631 $ (747,327) $ 15,665
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income [3] 59,790       57,932   1,858                  
Other comprehensive income (loss), net of tax (3,983)     (3,983)                        
Cash dividends on common stock (29,362)   141   (29,503)                      
Cash dividends on preferred stock $ (13,649)       (13,649)                      
Exercise of stock options (in shares) 541 540                            
Exercise of stock options $ 30,622 $ 6 30,616                          
Acquisition of Company common stock (in shares)   (32)                            
Acquisition of Company common stock (2,701)         (2,701)                    
Stock-based compensation expense 16,310   16,310                          
Issuance of restricted stock (in shares)   119                            
Issuance of restricted stock 0   (6,922)     6,922                    
Tax effect of restricted stock awards (3,974)   (3,974)                          
Distributions to noncontrolling interests (2,284)           (2,284)                  
Other (in shares)   24                            
Other 14   (1,115)   (253) 1,382                    
Ending balance (in shares) at Dec. 27, 2020   32,545                            
Ending balance at Dec. 27, 2020 (266,939) $ 453 254,103 (14,168) 219,158 (741,724) 15,239                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income [3] 122,346       120,016   2,330                  
Other comprehensive income (loss), net of tax 4,197     4,197                        
Repurchase and conversion of Series B Convertible Preferred Stock (in shares)   3,489                            
Repurchase and conversion of Series B Convertible Preferred Stock 64,168 $ 35 174,631   (110,498)                      
Cash dividends on common stock (40,356)   158   (40,514)                      
Cash dividends on preferred stock $ (4,121)       (4,121)                      
Exercise of stock options (in shares) 212 212                            
Exercise of stock options $ 11,969 $ 2 11,967                          
Acquisition of Company common stock (in shares)   (594)                            
Acquisition of Company common stock (72,499)         (72,499)                    
Stock-based compensation expense 16,919   16,919                          
Issuance of restricted stock (in shares)   132                            
Issuance of restricted stock 0   (6,970)     6,970                    
Tax effect of restricted stock awards (5,847)   (5,847)                          
Distributions to noncontrolling interests (2,357)           (2,357)                  
Other (in shares)   13                            
Other $ 62   165   (884) 781                    
Ending balance (in shares) at Dec. 26, 2021 35,800 35,797                            
Ending balance at Dec. 26, 2021 $ (172,458) $ 490 445,126 (9,971) 183,157 (806,472) 15,212                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Net income [3] 68,775       67,772   1,003                  
Other comprehensive income (loss), net of tax (164)     (164)                        
Cash dividends on common stock $ (54,767)   210   (54,977)                      
Exercise of stock options (in shares) 82 82                            
Exercise of stock options $ 4,036 $ 1 4,035                          
Acquisition of Company common stock (in shares)   (1,343)                            
Acquisition of Company common stock (125,000)         (125,000)                    
Stock-based compensation expense 18,388   18,388                          
Issuance of restricted stock (in shares)   285                            
Issuance of restricted stock 0   (8,443)     8,443                    
Tax effect of restricted stock awards (in shares)   (94)                            
Tax effect of restricted stock awards (9,546)   (9,546)                          
Distributions to noncontrolling interests (486)           (486)                  
Other (in shares)   9                            
Other $ 558   59   (96) 595                    
Ending balance (in shares) at Dec. 25, 2022 34,700 34,736                            
Ending balance at Dec. 25, 2022 $ (270,664) $ 491 $ 449,829 $ (10,135) $ 195,856 $ (922,434) $ 15,729                  
[1] (3)At December 25, 2022, the accumulated other comprehensive loss of $10,135 was comprised of net unrealized foreign currency translation loss of $8,696 and a net unrealized loss on the interest rate swap agreements of $1,439. At December 26, 2021, the accumulated other comprehensive loss of $9,971 was comprised of net unrealized foreign currency translation loss of $4,869 and a net unrealized loss on the interest rate swap agreements of $5,102. At December 27, 2020, the accumulated other comprehensive loss of $14,168 was comprised of net unrealized foreign currency translation loss of $3,793 and a net unrealized loss on the interest rate swap agreements of $10,375.
[2] (2)As of December 30, 2019, the Company adopted Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” See “Note 10. Allowance for Credit Losses” of “Notes to Consolidated Financial Statements” for additional information.
[3] (1)Net income to the Company for the years ended December 25, 2022, December 26, 2021 and December 27, 2020 excludes $574, $2,609 and $824, respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.